Literature DB >> 21810839

Micafungin therapy in a critically ill, morbidly obese patient.

Amanda Zomp, P Brandon Bookstaver, Yasir Ahmed, J Elliot Turner, Christie King.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21810839     DOI： 10.1093/jac/dkr323

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  3 in total

1.  Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.

Authors:  Renátó Kovács; Qasem Saleh; Aliz Bozó; Zoltán Tóth; Rudolf Gesztelyi; Tamás Kardos; Gábor Kardos; István Takacs; László Majoros
Journal:  Mycopathologia       Date:  2017-07-11       Impact factor: 2.574

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.

Authors:  Roeland E Wasmann; Eline W Muilwijk; David M Burger; Paul E Verweij; Catherijne A Knibbe; Roger J Brüggemann
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

3.  Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.

Authors:  Emilio Maseda; Santiago Grau; Sonia Luque; Maria-Pilar Castillo-Mafla; Alejandro Suárez-de-la-Rica; Ana Montero-Feijoo; Patricia Salgado; Maria-Jose Gimenez; Carlos A García-Bernedo; Fernando Gilsanz; Jason A Roberts
Journal:  Crit Care       Date:  2018-04-15       Impact factor: 9.097
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.